The information contained in this Item 7.01 and in the accompanying exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On July 10, 2012, Theravance, Inc. (the "Company") issued a press release announcing topline results from Phase 2b study 0084 of TD-1211, an investigational, orally administered, peripherally selective, multivalent inhibitor of the mu opioid receptor for the treatment of opioid-induced constipation. Dr. Mathai Mammen, the Company's Senior Vice President, Research and Early Clinical Development, will discuss these results on a conference call today at 5:00 p.m. Eastern Daylight Time. A copy of the press release and the slide presentation are furnished as Exhibit 99.1 and Exhibit 99.2 to this report and are incorporated herein by reference.

(d) Exhibits.

Exhibit                                      Description

Exhibit 99.1    Press Release of Theravance, Inc. dated July 10, 2012

Exhibit 99.2    Theravance TD-1211 Phase 2b Study Results Slide Presentation dated
                July 10, 2012